1
|
Reis RI, Nogueira MD, Campanha-Rodrigues AL, Pereira LM, Andrade MCC, Parreiras-E-Silva LT, Costa-Neto CM, Mortara RA, Casarini DE. The binding of captopril to angiotensin I-converting enzyme triggers activation of signaling pathways. Am J Physiol Cell Physiol 2018; 315:C367-C379. [PMID: 29874111 DOI: 10.1152/ajpcell.00012.2016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Hypertension is a global health problem, and angiotensin I (ANG I)-converting enzyme (ACE) inhibitors are largely used to control this pathology. Recently, it has been shown that ACE can also act as a transducer signal molecule when its inhibitors or substrates bind to it. This new role of ACE could contribute to understanding some of the effects not explained by its catalytic activity only. In this study, we investigated signaling pathway activation in Chinese hamster ovary (CHO) cells stably expressing ACE (CHO-ACE) under different conditions. We also investigated gene modulation after 4 h and 24 h of captopril treatment. Our results demonstrated that CHO-ACE cells when stimulated with ANG I, ramipril, or captopril led to JNK and ERK1/2 phosphorylation. To verify any physiological role at the endogenous level, we made use of primary cultures of mesangial cells from spontaneously hypertensive rats (SHR) and Wistar rats. Our results showed that ERK1/2 activation occurred mainly in primary cultures of mesangial cells from SHR rats upon captopril stimulation, suggesting that this signaling pathway could be differentially regulated during hypertension. Our results also showed that captopril treatment leads to a decrease of cyclooxygenase 2, interleukin-1β, and β-arrestin2 and a significant increase of AP2 gene expression levels. Our findings strengthen the fact that, in addition to the blockage of enzymatic activity, ACE inhibitors also trigger signaling pathway activation, and this may contribute to their beneficial effects in the treatment of hypertension and other pathologies.
Collapse
Affiliation(s)
- Rosana I Reis
- Department of Medicine, Nephrology Division, Escola Paulista de Medicina, Federal University of São Paulo , São Paulo , Brazil
| | - Marie D Nogueira
- Department of Medicine, Nephrology Division, Escola Paulista de Medicina, Federal University of São Paulo , São Paulo , Brazil
| | - Ana Lucia Campanha-Rodrigues
- Department of Medicine, Nephrology Division, Escola Paulista de Medicina, Federal University of São Paulo , São Paulo , Brazil
| | - Larissa Miranda Pereira
- Department of Medicine, Nephrology Division, Escola Paulista de Medicina, Federal University of São Paulo , São Paulo , Brazil
| | - Maria Claudina C Andrade
- Hospital Israelita Albert Einstein, Instituto Israelita de Ensino e Pesquisa , São Paulo , Brazil
| | - Lucas T Parreiras-E-Silva
- Department of Biochemistry and Immunology, Faculty of Medicine at Ribeirao Preto - University of São Paulo , Ribeirão Preto , Brazil
| | - Claudio M Costa-Neto
- Department of Biochemistry and Immunology, Faculty of Medicine at Ribeirao Preto - University of São Paulo , Ribeirão Preto , Brazil
| | - Renato Arruda Mortara
- Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo , São Paulo , Brazil
| | - Dulce E Casarini
- Department of Medicine, Nephrology Division, Escola Paulista de Medicina, Federal University of São Paulo , São Paulo , Brazil
| |
Collapse
|
2
|
Campanha-Rodrigues AL, Grazioli G, Oliveira TC, Campos-Lisbôa ACV, Mares-Guia TR, Sogayar MC. Therapeutic Potential of Laminin–Biodritin Microcapsules for Type 1 Diabetes Mellitus. Cell Transplant 2015; 24:247-61. [DOI: 10.3727/096368913x675160] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Pancreatic islet microencapsulation constitutes an attractive therapy for type 1 diabetes mellitus; however, long-term β-cell function remains a major problem. Loss of extracellular matrix interactions during islet isolation dramatically affects β-cell viability. We have previously shown beneficial effects of laminin (LN) in human islet cultures. Herein, we investigated whether LN could improve the outcome of transplantation after islet microencapsulation in Biodritin, an alginate-based material. To test LN-Biodritin stability, microcapsules were subjected to different types of in vitro stress. Focusing on biocompatibility, empty microcapsules were coincubated with the RAW 264.7 macrophage cell line for up to 24 h, and empty beads were implanted IP in mice and retrieved for analyses after 7 and 30 days. Upon culturing for 48 h, mRNA, protein levels, and caspase 3 activity were evaluated in islets microencapsulated with LN-Biodritin. Mice rendered diabetic by streptozotocin injection were transplanted with microencapsulated islets, followed by assessment of body weight, glycemia, and graft function (evaluated by OGTT). Graft efficiency was observed upon microencapsulated islet explantation. The results obtained showed that LN-Biodritin microcapsules were as stable and biocompatible as Biodritin. Modulation of mRNA and protein levels suggested protection against apoptosis and islet stress. Mice transplanted with LN-Biodritin microencapsulated islets presented a better outcome at 198 days postsurgery. Graft explantation led animals to hyperglycemia. In conclusion, LN-Biodritin constitutes a very promising biomaterial for islet transplantation.
Collapse
Affiliation(s)
- Ana Lucia Campanha-Rodrigues
- Chemistry Institute, Biochemistry Department, Cell and Molecular Therapy Center (NUCEL/NETCEM), School of Medicine, University of São Paulo, São Paulo, SP, Brazil
| | - Gisella Grazioli
- Chemistry Institute, Biochemistry Department, Cell and Molecular Therapy Center (NUCEL/NETCEM), School of Medicine, University of São Paulo, São Paulo, SP, Brazil
- Cell Protect Biotechnology Ltda., São Paulo, SP, Brazil
| | - Talita C. Oliveira
- Chemistry Institute, Biochemistry Department, Cell and Molecular Therapy Center (NUCEL/NETCEM), School of Medicine, University of São Paulo, São Paulo, SP, Brazil
| | - Ana Carolina V. Campos-Lisbôa
- Chemistry Institute, Biochemistry Department, Cell and Molecular Therapy Center (NUCEL/NETCEM), School of Medicine, University of São Paulo, São Paulo, SP, Brazil
- Cell Protect Biotechnology Ltda., São Paulo, SP, Brazil
| | - Thiago R. Mares-Guia
- Chemistry Institute, Biochemistry Department, Cell and Molecular Therapy Center (NUCEL/NETCEM), School of Medicine, University of São Paulo, São Paulo, SP, Brazil
- Cell Protect Biotechnology Ltda., São Paulo, SP, Brazil
| | - Mari C. Sogayar
- Chemistry Institute, Biochemistry Department, Cell and Molecular Therapy Center (NUCEL/NETCEM), School of Medicine, University of São Paulo, São Paulo, SP, Brazil
| |
Collapse
|
3
|
Guabiraba R, Campanha-Rodrigues AL, Souza AL, Santiago HC, Lugnier C, Alvarez-Leite J, Lemos VS, Teixeira MM. The flavonoid dioclein reduces the production of pro-inflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive oxygen species. Eur J Pharmacol 2010; 633:85-92. [DOI: 10.1016/j.ejphar.2010.01.021] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2009] [Revised: 01/11/2010] [Accepted: 01/20/2010] [Indexed: 12/20/2022]
|